Literature DB >> 3091287

Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.

B Cercek, A S Lew, H Hod, J Yano, N K Reddy, W Ganz.   

Abstract

The effect of pretreatment with heparin on lysis of arterial thrombi by tissue-type plasminogen activator (rt-PA) was studied in 19 dogs. Copper coil-induced carotid artery thrombi were weighed, inserted into the femoral arteries, and exposed to a 15 min infusion of rt-PA at 10 micrograms/kg/min either with (n = 6 thrombi) or without pretreatment with a 200 unit/kg bolus of heparin (n = 6 thrombi). The infusion of rt-PA without pretreatment reduced the thrombus weight by 27.6 +/- 7.4%, while infusion of rt-PA with pretreatment reduced it by 79.1 +/- 12.3% (p less than .0001). To test the hypothesis that heparin enhanced thrombolysis by preventing continued incorporation of new fibrin into the thrombus during thrombolysis we repeated the experiments using pretreatment with 8 U/kg of ancrod, which rapidly depletes fibrinogen. Pretreatment with ancrod (n = 6 thrombi) depleted fibrinogen and enhanced the lytic effect of rt-PA to a similar degree as pretreatment with heparin, resulting in a 67.6 +/- 12.3% (NS) decrease in thrombus weight. We conclude that heparin significantly enhances the thrombolytic effect of rt-PA, probably by preventing new fibrin formation and its incorporation into the thrombus during lysis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3091287     DOI: 10.1161/01.cir.74.3.583

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

2.  Issues Regarding the Use of Heparin Following Streptokinase Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 3.  Thrombolysis. An approach still on the move.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-02       Impact factor: 9.546

Review 4.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

5.  Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.

Authors:  P Golino; M Rosolowsky; S K Yao; J McNatt; F De Clerck; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

Review 6.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

Review 7.  Thrombolysis in thromboembolic diseases.

Authors:  D C Gulba; R Dechend
Journal:  Ann Hematol       Date:  1994-10       Impact factor: 3.673

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.